The COMPACT RENAL team provided a range of insights to and overviews of issues relating to iron deficiency anemia in 2016; below are some of the highlights.
The kinetics of oral and IV iron
In an interview recorded for COMPACT RENAL, Professor Tomas Ganz explained the differences in uptake kinetics of oral and intravenous iron, and the impact this has on their clinical efficacy, particularly in the presence of inflammation.
Designing clinical trials for IV iron
Professor Iain Macdougall discussed the strengths and limitations of previous randomised controlled trials of IV iron alongside the best clinical endpoints for future studies, including those which will help elucidate any non-haematological benefits. He also discussed the strength of the PIVOTAL trial design in answering outstanding questions regarding the use of IV iron.
The value of observational studies
In this expert video Professor Kamyar Kalantar-Zadeh recognised the importance of the PIVOTAL trial, but highlighted the value of observational studies in providing an insight to how guidelines are implemented and responses to therapies in the ‘real-world’ setting.
News & views
One highlight of the publications for 2016 was analysis of the FIND-CKD safety data by Professor Simon Roger and colleagues. An extension of the original analysis, they found no difference in adverse events between patients treated to a high or low ferritin target or with oral iron.
Conclusions of the KDIGO Controversies Conference were published in 2016, and summarized by the COMPACT RENAL team in two parts. The first discussed the evidence and research recommendations regarding iron overload and oxidative stress in relation to IV iron use, while the second covered infection risk and hypersensitivity reactions.
A downloadable speaker’s guide has also been made available on COMPACT, summarizing the conclusions of the KDIGO Controversies Conference regarding: iron deficiency vs. overload, oxidative stress, infection risk and hypersensitivity.